Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medication Optimization for ADHD (MOVA)
2016-002474-13Phase 4Active
- Sponsor
- Innovatiefonds Zorgverzekeraars
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of methylphenidate in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Innovatiefonds Zorgverzekeraars. Primary endpoint: Optimization of methylphenidate use with placebo-controlled titration. Started Apr 2017; status: active.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2016-002474-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002474-13.